South San Francisco, Calif., February 4, 2022 – Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced that company management will participate in the following upcoming investor conferences:
4th Annual Guggenheim Oncology Conference
Craig Gibbs, Ph.D., will present a corporate overview on Friday, February 11, 2022 at 1:00 p.m. ET (10:00 a.m. PT). Company management will also participate in 1×1 meetings on Friday, February 11, 2022.
SVB Leerink 11th Annual Global Healthcare Conference
Company management will participate in 1×1 meetings on Monday, February 14 and Tuesday, February 15, 2022.
About Asher Bio
Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmune and infectious diseases. Asher Bio was founded by Ivana Djuretic and Andy Yeung with support from Third Rock Ventures and is located in South San Francisco. For more information, please visit www.asherbio.com and follow us on Twitter @AsherBio and on LinkedIn.
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
Investor Contact
Hannah Deresiewicz, Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com
This links to an external website.